Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30744738 | 1.00 | MRGPRX4 (0.63) | MRGPRX4AKR1C3KMT2ANPSR1MEN1 | |
| SCHEMBL28976599 | 0.85 | AKR1C3 (0.58) | MRGPRX4AKR1C3KMT2ARAB9ANR4A2 | |
| SCHEMBL14033164 | 0.85 | ATM (0.59) | MRGPRX4AKR1C3KMT2ANPSR1MEN1 | |
| SCHEMBL30668123 | 0.85 | ATM (0.59) | MRGPRX4AKR1C3KMT2ANPSR1MEN1 | |
| SCHEMBL13906281 | 0.83 | MRGPRX4 (0.62) | MRGPRX4KMT2AMEN1MAPTRAB9A | |
| SCHEMBL2277217 | 0.83 | KMT2A (0.54) | KMT2ANPSR1MEN1MAPTRAB9A | |
| SCHEMBL2762181 | 0.83 | PARP1 (0.62) | KMT2ANPSR1MEN1MAPTRAB9A | |
| SCHEMBL9567403 | 0.83 | KMT2A (0.57) | MRGPRX4KMT2ANPSR1MEN1MAPT | |
| SCHEMBL27935297 | 0.82 | AKR1C3 (0.63) | MRGPRX4AKR1C3KMT2ARAB9ANR4A2 | |
| SCHEMBL978712 | 0.82 | AKR1C3 (0.54) | MRGPRX4AKR1C3KMT2ANPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | claimed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | claimed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | claimed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | claimed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | claimed |
| CN-103992220-B | A kind of preparation method of roflumilast intermediate | INSTITUTE OF MATERIA MEDICA, SHANDONG ACADEMY OF MEDICAL SCIENCES (CN) | 2015-11-18 | — | — | CN | claimed |
| CN-103992220-A | Method for preparing roflumilast intermediate | INST OF MATERIA MEDICA SHANDONG ACADEMY OF MEDICAL SCIENCES | 2014-08-20 | — | — | CN | claimed |
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | disclosed |
| EP-4612134-A1 | DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | disclosed |
| EP-0084893-B1 | 4H-3,1-BENZOXAZIN DERIVATIVES, METHODS FOR THEIR PREPARATION, AND THEIR USE FOR COMBATTING UNDESIRABLE VEGETATION | BASF Aktiengesellschaft (DE) | 1987-01-14 | — | — | EP | disclosed |
| US-RE32087-E | 4H-3,1-Benzoxazine derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1986-02-25 | — | — | US | disclosed |
| EP-0017931-B1 | 4H-3,1-BENZOXAZINE DERIVATIVES, METHODS OF THEIR PREPARATION AND THEIR USE IN COMBATING UNDESIRABLE VEGETATION | BASF Aktiengesellschaft (DE) | 1984-03-07 | — | — | EP | disclosed |
| EP-0084893-A2 | 4H-3,1-Benzoxazin derivatives, methods for their preparation, and their use for combatting undesirable vegetation | BASF Aktiengesellschaft (DE) | 1983-08-03 | — | — | EP | disclosed |
| US-4315766-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | disclosed |
| EP-0017931-A2 | 4H-3,1-Benzoxazine derivatives, methods of their preparation and their use in combating undesirable vegetation | BASF Aktiengesellschaft (DE) | 1980-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | MRGPRX4 776/4885AKR1C3 366/4885KMT2A 2100/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | MRGPRX4 1607/4885AKR1C3 431/4885KMT2A 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.